Injectable devices as cell factory implants for therapeutic antibody production

Introduction: Antibodies have emerged as a leading biotherapeutic class, but their subcutaneous or intravenous administrations is limited by the rate of systemic clearance, necessitating frequent dosing which is inconvenient and costly for patients. A promising approach is the use of encapsulated recombinant cells as a viable source for continuous antibody production. We designed minimally invasive subcutaneous injectable devices to deliver antibody-producing cell factories for sustained antibody delivery from a fixed payload of cells. These macro devices prevent cell escape & can be safely removed.

Daniel Bernards – Senior Scientist, University of California, San Francisco; Bhushan Kharbikar – Postdoctoral Fellow, University of California, San Francisco; Daria Smuk – Student, School of Engineering, Brown University; Brendan Knittle – Masters Student, School of Engineering, Brown University; Jean Jerome – PhD Student, School of engineering, Brown University; Akram Abassi – Postdoctoral Fellow, School of Engineering, Brown University; Meerab Aziz – student, School of Engineering, Brown University; Kareem Ebeid – Postdoctoral Fellow, School of Engineering, Brown University; Anthony Davis – PhD Student, Department of Bioengineering, Rice University; Omid Veiseh – Professor, Department of Bioengineering, Rice University; Tejal Desai – Dean of School of engineering, Brown University